GS
MDGL icon

GTS Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History

GTS Securities’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,900
Closed -$4.44M – 2932
2024
Q3 		$4.44M Buy
20,900
+7,700
+58% +$1.97M 0.01% 967
2024
Q2 		$3.7M Sell
13,200
-6,400
-33% -$1.52M 0.01% 1057
2024
Q1 		$5.23M Sell
19,600
-3,800
-16% -$895K 0.01% 832
2023
Q4 		$5.41M Buy
23,400
+9,800
+72% +$1.71M 0.01% 942
2023
Q3 		$1.99M Buy
+13,600
New +$2.56M ﹤0.01% 1523

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GTS Securities's MDGL Position: Q2 2026 in Review

GTS Securities opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 392 shares worth $210K. The stake represents ﹤0.01% of the portfolio and ranks #1180 among its holdings. This is a return to the name: GTS Securities previously reported a position in MDGL as recently as Q3 2024.

GTS Securities first reported a position in MDGL in Q3 2023 and has held it in 6 quarters since. The position peaked at $1.31M in Q3 2024. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • GTS Securities held 392 shares of Madrigal Pharmaceuticals worth $210K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new GTS Securities position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of GTS Securities's portfolio in Q2 2026, its #1180 holding.
  • GTS Securities first reported a position in Madrigal Pharmaceuticals in Q3 2023 and has held it in 6 quarters since.
  • GTS Securities's Madrigal Pharmaceuticals position peaked at $1.31M in Q3 2024.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.